in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Codexis and Merck Develop Prototype Enzyme-Based Method for Production of an Active Ingredient
12:31 AM MDT | April 4, 2012 | Deepti Ramesh
Codexis says that collaborative research by Merck & Co. (Whitehouse Station, NJ) and Codexis scientists to develop an enzyme-based production method for a key intermediate in the production of boceprevir has been recently published in the Journal of the American Chemical Society (JACS). Boceprevir is the active ingredient in Merck's Victrelis capsules for the treatment of chronic hepatitis C. Codexis is a developer of industrial enzymes to enable the production of biofuels, biobased chemicals and pharmaceutical intermediates. “The Codexis technology has...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee